PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.
PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.
The major companies are rigorously investing in R&D of PEGylated drugs and have a good number of molecules in the pipeline. For instance, UCB and Biogen are evaluating the safety and efficacy of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is being developed for the treatment of systemic lupus erythematosus.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8436
However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period.
Market Dynamics
The Global PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer is creating a demand for effective drugs. The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.
Segmentation
The Global PEGylated Drugs Market has been segmented into molecule, indication, and region.
On the basis of molecule, the global PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others. PEGylated protein is estimated to account for the largest market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. For instance, in 2018, Coherus Biosciences has gained FDA approval for its Pegfilgrastim biosimilar, Udenyca (Pegfilgrastim-cbqv). Udenyca is a leukocyte growth factor used to decrease the incidence of infection in patients with non-myeloid malignancies.
On the basis of indication, the Global PEGylated Drugs Market has been segregated into cancer, hemophilia, hepatitis, gout, and others.
Regional Analysis
The Global PEGylated Drugs Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounted for a market share of 65.73% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.
Europe was the second-largest Global PEGylated Drugs Market in 2018. The rising efforts by the government to reduce chronic disease burden owing to the rising occurrence of cancer in the region is projected to drive the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market.
The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.
Prominent Players
The Prominent Players in the Global PEGylated Drugs Market Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/pegylated-drugs-market-8436
No comments:
Post a Comment